Mutations in the HIV-1 3'-Polypurine Tract Can Confer Dolutegravir Resistance.
作者信息
Dekker José G, Klaver Bep, Berkhout Ben, Das Atze T
机构信息
Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdamgrid.7177.6, Amsterdam, The Netherlands.
出版信息
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0102721. doi: 10.1128/AAC.01027-21. Epub 2021 Oct 11.
Abstract
摘要
相似文献
1
Mutations in the HIV-1 3'-Polypurine Tract Can Confer Dolutegravir Resistance.HIV-1 3'-多聚嘌呤序列中的突变可导致对多替拉韦产生耐药性。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0102721. doi: 10.1128/AAC.01027-21. Epub 2021 Oct 11.
2
Reverse transcription of HIV-1 2-LTR circle transcripts does frequently cause 3'-polypurine tract mutations implicated in dolutegravir resistance.HIV-1 2-LTR环状转录本的逆转录确实经常导致与多替拉韦耐药性相关的3'-多聚嘌呤序列突变。
J Virol. 2024 Jun 13;98(6):e0033524. doi: 10.1128/jvi.00335-24. Epub 2024 May 24.
3
Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.整合酶抑制剂耐药突变的监测用于传播的 HIV-1 药物耐药性。
J Antimicrob Chemother. 2020 Jan 1;75(1):170-182. doi: 10.1093/jac/dkz417.
4
Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.突变位于整合酶基因之外可赋予 HIV-1 整合酶链转移抑制剂耐药性。
mBio. 2017 Sep 26;8(5):e00922-17. doi: 10.1128/mBio.00922-17.
5
Effect of Dolutegravir and Sertraline on the Blood Brain Barrier (BBB).多替拉韦和舍曲林对血脑屏障（BBB）的影响。
J Neuroimmune Pharmacol. 2020 Mar;15(1):7-9. doi: 10.1007/s11481-020-09904-z. Epub 2020 Jan 15.
6
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.多替拉韦治疗人类免疫缺陷病毒感染经治青少年的长期安全性和疗效：IMPACT P1093 研究结果。
J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):159-165. doi: 10.1093/jpids/piy139.
7
8
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.评估接受整合酶抑制剂治疗的患者中 HIV-1 整合酶耐药性的出现和演变。
J Glob Antimicrob Resist. 2020 Mar;20:163-169. doi: 10.1016/j.jgar.2019.07.015. Epub 2019 Jul 19.
9
Dolutegravir drug-resistance monitoring in Africa.非洲地区多替拉韦耐药性监测
Lancet HIV. 2021 Nov;8(11):e664-e666. doi: 10.1016/S2352-3018(21)00268-X.
10
Is resistance to dolutegravir possible when this drug is used in first-line therapy?当多替拉韦用于一线治疗时，是否有可能出现对它的耐药性？
Viruses. 2014 Aug 27;6(9):3377-85. doi: 10.3390/v6093377.
引用本文的文献
1
Elucidating the mechanism by which HIV-1 nucleocapsid mutations confer resistance to integrase strand transfer inhibitors.阐明HIV-1核衣壳突变赋予整合酶链转移抑制剂耐药性的机制。
Sci Adv. 2025 Sep 12;11(37):eadz8980. doi: 10.1126/sciadv.adz8980.
2
Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial.在VESTED随机抗逆转录病毒治疗试验中对垂直传播病例的HIV耐药性进行特征分析。
J Acquir Immune Defic Syndr. 2024 Aug;96(4):385-392. doi: 10.1097/qai.0000000000003435.
3
Reverse transcription of HIV-1 2-LTR circle transcripts does frequently cause 3'-polypurine tract mutations implicated in dolutegravir resistance.HIV-1 2-LTR环状转录本的逆转录确实经常导致与多替拉韦耐药性相关的3'-多聚嘌呤序列突变。
J Virol. 2024 Jun 13;98(6):e0033524. doi: 10.1128/jvi.00335-24. Epub 2024 May 24.
4
HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis.基于多替拉韦的抗逆转录病毒治疗患者中的 HIV-1 耐药性：一项协作队列分析。
Lancet HIV. 2023 Nov;10(11):e733-e741. doi: 10.1016/S2352-3018(23)00228-X. Epub 2023 Oct 10.
5
5-Nitro-3-(2-(4-phenylthiazol-2-yl)hydrazineylidene)indolin-2-one derivatives inhibit HIV-1 replication by a multitarget mechanism of action.5-硝基-3-(2-(4-苯基噻唑-2-基)腙基)吲哚啉-2-酮衍生物通过多靶点作用机制抑制 HIV-1 复制。
Front Cell Infect Microbiol. 2023 Jun 23;13:1193280. doi: 10.3389/fcimb.2023.1193280. eCollection 2023.
6
HIV-1 3'-Polypurine Tract Mutations Confer Dolutegravir Resistance by Switching to an Integration-Independent Replication Mechanism via 1-LTR Circles.HIV-1 3'-端多聚嘧啶区突变通过 1-LTR 环切换为整合非依赖型复制机制从而赋予对多替拉韦的耐药性。
J Virol. 2023 May 31;97(5):e0036123. doi: 10.1128/jvi.00361-23. Epub 2023 May 1.
7
Drug Resistance to Integrase Strand-Transfer Inhibitors among HIV-1-Infected Adults in Guangdong, China.中国广东HIV-1感染成人中对整合酶链转移抑制剂的耐药性
Pathogens. 2022 Nov 10;11(11):1321. doi: 10.3390/pathogens11111321.
8
Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir.HIV-1 链转移整合酶抑制剂卡博特韦耐药的基因型相关性。
Antiviral Res. 2022 Dec;208:105427. doi: 10.1016/j.antiviral.2022.105427. Epub 2022 Sep 30.
9
Identification of an integrase-independent pathway of retrotransposition.逆转录转座整合酶非依赖途径的鉴定。
Sci Adv. 2022 Jul;8(26):eabm9390. doi: 10.1126/sciadv.abm9390. Epub 2022 Jun 29.
10
Multimodal Functionalities of HIV-1 Integrase.HIV-1 整合酶的多模态功能。
Viruses. 2022 Apr 28;14(5):926. doi: 10.3390/v14050926.
本文引用的文献
1
Tax Induces the Recruitment of NF-κB to Unintegrated HIV-1 DNA To Rescue Viral Gene Expression and Replication.税收诱导 NF-κB 招募到未整合的 HIV-1 DNA 以挽救病毒基因表达和复制。
J Virol. 2021 Jun 10;95(13):e0028521. doi: 10.1128/JVI.00285-21.
2
Mutations in the HIV-1 3'-Polypurine Tract and Integrase Strand Transfer Inhibitor Resistance.HIV-1 3'-多聚嘌呤序列突变与整合酶链转移抑制剂耐药性
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.02432-20.
3
Reversal of Epigenetic Silencing Allows Robust HIV-1 Replication in the Absence of Integrase Function.逆转表观遗传沉默可使 HIV-1 在没有整合酶功能的情况下进行稳健复制。
mBio. 2020 Jun 2;11(3):e01038-20. doi: 10.1128/mBio.01038-20.
4
Authentication Analysis of MT-4 Cells Distributed by the National Institutes of Health AIDS Reagent Program.美国国立卫生研究院艾滋病试剂计划分发的 MT-4 细胞的鉴定分析。
J Virol. 2019 Nov 26;93(24). doi: 10.1128/JVI.01390-19. Print 2019 Dec 15.
5
Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle.HIV-1 包膜糖蛋白中的突变可以广泛拯救病毒复制周期多个步骤中的阻断。
Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):9040-9049. doi: 10.1073/pnas.1820333116. Epub 2019 Apr 11.
6
Reply to Das and Berkhout, "How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir".对达斯和伯克霍特的回复：“HIV-1 RNA基因组中的多聚嘌呤序列变化如何导致对整合酶抑制剂多替拉韦产生耐药性”
mBio. 2018 May 29;9(3):e00623-18. doi: 10.1128/mBio.00623-18.
7
How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir.HIV-1 RNA基因组中的多嘌呤序列变化如何导致对整合酶抑制剂多替拉韦产生耐药性。
mBio. 2018 Apr 10;9(2):e00006-18. doi: 10.1128/mBio.00006-18.
8
HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy.多替拉韦维持治疗失败的患者中 HIV-1 耐药性的动态变化。
J Infect Dis. 2018 Jul 24;218(5):688-697. doi: 10.1093/infdis/jiy176.
9
Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.突变位于整合酶基因之外可赋予 HIV-1 整合酶链转移抑制剂耐药性。
mBio. 2017 Sep 26;8(5):e00922-17. doi: 10.1128/mBio.00922-17.
10
Unique morphological alterations of the HTLV-I transformed C8166 cells by infection with HIV-1.人嗜T淋巴细胞病毒I型（HTLV-I）转化的C8166细胞经人免疫缺陷病毒1型（HIV-1）感染后的独特形态学改变。
Pathol Oncol Res. 2000;6(1):27-37. doi: 10.1007/BF03032655.
Zotero 插件